The Hindu
int · 4 hrs ago
AI scored
Aurobindo Pharma shares gain on U.S. FDA’s VAI classification of oral solid dosage unit
75Accuracy
centreBias
0Ratings
💬 0Comments
AI Analysis
Accuracy 75/100
Partisan intensity 15/100
ObjectivePartisan
Centre / Neutral ✓ Fair headline
Aurobindo Pharma's share price rose over 3% following the U.S. FDA's VAI (Voluntary Action Indicated) classification of its oral solid dosage unit, with shares reaching near their 52-week high.
Aurobindo Pharma shares gain on U.S. FDA’s VAI classification of oral solid dosage unit
Around 2 p.m., Aurobindo Pharma shares were more than 3% higher at ₹1,475 each after touching the 52 week high of ₹1,481.80
Discussion 0 comments
Sort:
?
No comments yet — be the first to start the discussion!